Clinical features of hepatitis C patients with failure or recurrence after treatment with pegylated interferon-α combined with ribavirin and the clinical effect of direct-acting antiviral agents
-
摘要: 目的探讨真实世界中聚乙二醇干扰素α联合利巴韦林的标准方案(PR方案)治疗失败和复发患者的临床特征及不同直接抗病毒药物(DAA)治疗方案对PR治疗失败和复发患者的疗效。方法回顾性纳入2014年3月-2018年1月兰州市第一人民医院门诊、住院经标准PR方案治疗失败和复发的慢性丙型肝炎及丙型肝炎相关代偿期肝硬化患者106例,其中男54例,女52例,根据患者PR治疗应答情况分为失败组13例,复发组51例,持续病毒学应答组42例。三组患者行IL-28B基因位点rs12979860和rs8099917检测,基线生化、Cobas HCV RNA、病毒基因分型等检测,比较三组之间的差异。观察PR治疗失败及复发患者接受不同DAA方案的疗效。计数资料组间比较采用χ2检验,计量资料多组间比较采用单因素方差分析。结果失败组和复发组年龄明显高于应答组,三组比较差异有统计学意义(F=14. 05,P <0. 001)。失败组病毒基因型以1b型为主,占84. 6%,复发组病毒基因型以2a为主,占72. 5%,与应答组三组比较差异有统计学意义(χ2=17. 269,P...Abstract: Objective To investigate the clinical features of patients with failure or recurrence after treatment with PEG-IFN combined with ribavirin( PR regimen) in the real world and the clinical effect of different direct-acting antiviral agent( DAA) regimens in such patients. Methods A retrospective analysis was performed for the clinical data of 106 patients with chronic hepatitis C or hepatitis C-related compensated liver cirrhosis who attended the outpatient service or were hospitalized in The First Peoples' s Hospital of Lanzhou from March2014 to January 2018,and these patients experienced failure or recurrence after the treatment with the standard PR regimen. There were 54 male and 52 female patients. According to the response to PR treatment,the patients were divided into failure group with 13 patients,recurrence group with 51 patients,and sustained virologic response group with 42 patients. All patients underwent IL-28 B rs12979860/rs8099917 detection,baseline biochemical examination,Cobas HCV RNA test,and viral genotyping,and these results were compared between groups. The clinical outcomes of patients with failure or recurrence after PR treatment were observed after the treatment with different DAA regimens. The chi-square test was used for comparison of categorical data between groups; a one-way analysis of variance was used for comparison between multiple groups. Results The failure group and the recurrence group had a significantly higher age than the sustained virologic response group( F = 14. 05,P < 0. 001). Among the patients in the failure group,86. 4% had viral genotype 1 b,while among those in the recurrence group,72. 5% had viral genotype 2 a,and there was a significant difference between the three groups( χ2=17. 269,P = 0. 002). Among the patients in the failure group,92. 3% had a baseline HCV RNA level of ≥106 IU/L,and the failure group had a significantly higher proportion of such patients than the recurrence group and the sustained virologic response group( χ2= 10. 407,P =0. 005). There were no significant differences in sex and liver cirrhosis between the three groups( all P > 0. 05). Among the patients with primary treatment failure,100% patients had the non-protective genotype of IL-28 B rs12979860 CT/TT,and 92. 3% had the non-protective genotype of IL-28 B rs8099917 TG/GG; among the patients with recurrence,84. 3% patients had the non-protective genotype of IL-28 B rs12979860 CT/TT,and 86. 3% had the non-protective genotype of IL-28 B rs8099917 TG/GG; among the patients in the sustained virologic response group,85. 7% gad genotype CC at IL-28 B rs12979860 and 88. 1% had genotype TT at IL-28 B rs8099917.There were significant differences in the constituent ratios of rs12979860 and rs8099917 gene polymorphisms between the three groups( χ2= 57. 263 and 59. 651,both P < 0. 001). The patients with failure or recurrence after PR treatment achieved a sustained virologic response rate of 100% after the treatment with three different DAA regimens based on sofosbuvir. Conclusion Viral genotype and non-protective genotypes at IL-28 B rs12979860 and rs8099917 are influencing factors for failure and recurrence after PR treatment. The three different DAA regimens based on sofosbuvir achieves a sustained virologic response rate of 100% and has good safety in patients with failure or recurrence after PR treatment,which is not affected by the factors including IL-28 B single nucleotide polymorphism and viral replication level in the host.
-
Key words:
- hepatitis C,chronic /
- polyethylene glycols /
- interferons /
- antiviral agents /
- disease attributes /
- treatment outcome
-
[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol,2015,31(12):1961-1979.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1961-1979. [2] ZHANG YR,ZHOU N,LI XL,et al. Causes and countermeasures for relapse after drug withdrawal in patients with chronic hepatitis C[J]. J Clin Hepatol,2015,31(9):1434-1438.(in Chinese)张月荣,周宁,李象霖,等.慢性丙型肝炎患者停药后复发的影响因素分析[J].临床肝胆病杂志,2015,31(9):1434-1438. [3] ZHOU Y,YE XT,CHEN W,et al. The effects of interleukin-28B gene polymorphisms on antiviral treatment response in patients with chronic hepatitis C[J]. Chin Infect Dis J,2017,35(4):218-222.(in Chinese)周宇,叶晓婷,陈威,等.白细胞介素-28B基因多态性对慢性丙型肝炎患者抗病毒治疗应答的影响[J].中华传染病杂志,2017,35(4):218-222. [4] ECHEVERRIA N,CHIODI D,LOPEZ P,et al. IL28B gene polymorphism rs12979860,but not rs8099917,contributes to the occurrence of chronic HCV infection in Uruguayan patients[J]. Virol J,2018,15(1):40. [5] TAHERI S,AYGEN B,KORKMAZ K,et al. Characterization of the interleukin-28B gene rs12979860 C/T polymorphism in Turkish chronic hepatitis C patients and healthy individuals[J]. Balkan Med J,2015,32(2):147-155. [6] MATSUURA K,WATANABE T,TANAKA Y. Role of IL28B for chronic hepatitis C treatment toward personalized medicine[J]. J Gastroenterol Hepatol,2014,29(2):241-249. [7] RANJAN P,FLETCHER J,KADHAKRISHNAN M,et al. Association of interleukin-28B rsl2979860 and rs8099917 polymorphism with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent[J]. Indian J Med Microbiol,2016,34(3):335-341. [8] HOLMES JA,DESMOND PV,THOMOSON AJ,et al. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection[J]. J Viral Hepat,2012,19(10):677-684. [9] CHU TW,KULKARNI R,GANE EJ,et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C[J]. Gastroenterology,2012,142(4):790-795. [10] POORDAD F,MCCONE J,BACON BR,et al. Boceprevir for untreated chronic HCV genotype1 infection[J]. N Engl J Med,2011,364(13):1195-1206. [11] HE YJ,LIU ZH,HOU JL. Selection of direct-antiviral agents for chronic hepatitis C infection[J]. Chin J Hepatol,2018,26(3):169-172.(in Chinese)何雅婧,刘智泓,侯金林.直接抗病毒药物治疗慢性丙型肝炎的方案选择[J].中华肝脏病杂志,2018,26(3):169-172. [12] ZHANG Y,LENG XJ,YAN XB. Interaction between anti-HCV direct anti-viral agents and other drugs[J/CD]. Chin J Exp Clin Infect Dis:Electronic Edition,2017,11(2):105-110.(in Chinese)张莹,冷雪君,颜学兵.抗HCV直接抗病毒药与其他药物的相互作用[J/CD].中华实验和临床感染病杂志:电子版,2017,11(2):105-110. [13] YOUNOSSI ZM,STEPANOVA M,JACOBSON IM,et al. Sofosbuvir and velpatasvir with or without voxilaprevir in directacting antiviral-naive chronic hepatitis C:Patient-reported outcomes from POLARIS 2 and 3[J]. Aliment Pharmacol Ther,2018,47(2):259-267. [14] MARIO S,CARMINE M,STEFANIA D,et al. Virological patterns of HCV patients with failure to interferon-free regimens[J]. J Med Virol,2018,90(5):942-950. [15] BERDEN FA,AALDERING BR,GROENEWOUD H,et al. Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection:A systematic review and network meta-analysis[J]. Clin Gastroenterol Hepatol,2017,15(3):349-359. [16] ZHANG X,LI YG. Current status of the application of directacting antiviral agents in treatment of chronic hepatitis C and existing problems[J]. J Clin Hepatol,2018,34(4):853-857.(in Chinese)张熙,李用国.慢性丙型肝炎直接抗病毒药物应用现状及存在问题[J].临床肝胆病杂志,2018,34(4):853-857. 期刊类型引用(10)
1. 杨晓曼. γ-谷氨酰转移酶/血小板在乙肝肝硬化失代偿期患者中的表达及临床意义. 河南医学研究. 2024(08): 1407-1410 . 百度学术
2. 刘爱华,符建,陈小红. 瞬时超声弹性成像联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化价值研究. 实用肝脏病杂志. 2023(05): 634-637 . 百度学术
3. 肖少伟,杜亚哲. γ-谷氨酰转移酶/胆碱酯酶比值与γ-谷氨酰转移酶/血小板比值对慢性乙型肝炎患者肝纤维化程度的预测效能. 实用医技杂志. 2023(11): 812-815 . 百度学术
4. 张玉婷,施欢,李虤,沈波. FibroTouch联合GGT/PLT比值对诊断乙型肝炎肝纤维化的临床价值. 江西医药. 2022(02): 206-209+216 . 百度学术
5. 桑阿利. APRI、Fib-4和Fibroscan联合诊断慢性乙型肝炎肝纤维化程度的价值. 甘肃医药. 2022(10): 896-898 . 百度学术
6. 王晔恺,于倩,姚燕珍,罗雯斌,洪开听,鲍舟君. 对数几率回归模型构建联合预测因子对慢性乙型肝炎患者早期肝硬化诊断的临床应用. 中国卫生检验杂志. 2021(01): 90-93+97 . 百度学术
7. 陈兴,梁小桃. 肝瞬时弹性成像与天冬氨酸转氨酶/血小板指数在慢性乙型肝炎合并脂肪肝患者肝纤维化诊断中的应用价值. 中国当代医药. 2021(11): 60-62 . 百度学术
8. 黄腊平,陈焰. 基于Fibroscan技术的柴胡疏肝散对非酒精性脂肪肝患者临床疗效分析. 清远职业技术学院学报. 2020(02): 35-38 . 百度学术
9. 栗红江,何久胜,胡素玲,何福亮,田彦卿,刘震霞. 声辐射力脉冲成像技术、瞬时弹性成像技术及天冬氨酸氨基转移酶与血小板比率指数联合检测乙型肝炎肝纤维化程度临床效能. 临床军医杂志. 2020(09): 1090-1091+1094 . 百度学术
10. 熊静,林登娜,翁伟镇,陈俊峰,曹会娟,张绍全,张静,高隽,林炳亮. FIB-4联合血清PCⅢ、ⅣC评估乙型肝炎病毒相关肝纤维化. 国际病毒学杂志. 2020(05): 403-406 . 百度学术
其他类型引用(2)
-